News
Enter your email address to get Core One Labs News Alerts.
News
Enter your email address to get Core One Labs News Alerts.
Company News
Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
July 28, 2023
Vancouver, British Columbia, Canada – July 28, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more
Company News
Core One Labs Enters into Letter of Intent for First Sale of its Psychedelic Compounds
July 21, 2023
Vancouver, British Columbia, Canada – July 21, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Applauds California Assembly Health Committee’s Approval of Bill to Legalize Psychedelics
July 19, 2023
Vancouver, British Columbia, Canada – July 19, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One’s Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
July 11, 2023
Vancouver, British Columbia, Canada – July 11, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
Core One’s Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
July 07, 2023
Vancouver, British Columbia, Canada – July 7, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Applauds FDA’s Draft Guidance on Clinical Trials for Psychedelic Drugs
June 26, 2023
Vancouver, British Columbia, Canada – June 26, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more